Raphael Pharmaceutical Inc.
RAPH- Exchange
- OTC
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001415397
No open-market purchases or sales by Raphael Pharmaceutical Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Raphael Pharmaceutical Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Raphael Pharmaceutical Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Louria Hayon Igal | Chief Technology Officer | 1,349,000 | Apr 6, 2026 | 1 |
| Eliya Yehuda | Director | 352,000 | Mar 12, 2025 | 0 |
| Pilo Shlomo | Chief Executive Officer | 3,983,701 | Mar 11, 2025 | 0 |
| Dhadha Ajay Kumar | Director | 351,667 | Mar 6, 2025 | 0 |
| Ofir Guy | Chief Financial Officer | 1,266,455 | Mar 13, 2023 | 0 |
| Press Joseph | Director | 280,000 | Mar 13, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.